Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XPACE-1008
- Development stage
- Preclinical
- Lead developer
- Xanadu Bio
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
XPACE-1008 is an investigational mRNA-based therapeutic being developed by Xanadu Bio for the treatment of non-small cell lung cancer (NSCLC). The drug utilizes Xanadu Bio's proprietary poly(amine-co-ester) (PACE) polymer nanoparticle delivery platform to deliver mRNA encoding interleukin-2 (IL-2). Upon delivery, the mRNA is translated to express IL-2, which is intended to stimulate antitumor immune-cell activity and enhance the body's immune response against lung cancer cells. XPACE-1008 is currently in the discovery stage of development.
- Other names
- XPACE 1008XPACE1008XPACE-1008
Beyond the preview
Go deeper on XPACE-1008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XPACE-1008.